Can ribociclib treat advanced breast cancer?

Ribociclib (Ribociclib) has been proven to be one of the most effective drugs in the treatment of advanced breast cancer. Advanced breast cancer usually refers to an advanced stage of breast cancer that has spread to other tissues or organs outside of the breast, also known as metastatic breast cancer. In this case, the goal of treatment is to prolong the patient's survival and improve the quality of life.

Ribociclib is mainly used to treat hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which is one of the most common subtypes of breast cancer. It prevents cell proliferation and growth by inhibiting the activity of cyclin-dependent kinase 4/6 (CDK4/6). This effect helps control tumor growth and spread, thereby extending patients' progression-free survival (PFS).

Clinical trials have proven that ribociclib (ribociclib) used in combination with other endocrine therapy drugs (such as aromatase inhibitors), shows significant efficacy in the treatment of HR+, HER2- advanced breast cancer patients. This combination therapy can extend patients' PFS, slow disease progression, and potentially improve patients' overall survival.

Although ribociclib has shown promising efficacy in the treatment of advanced breast cancer, it is not a replacement for a single treatment regimen. Often, ribociclib is given in combination with other treatments, such as endocrine therapies, to comprehensively inhibit the growth and spread of tumors. Doctors will develop personalized treatment plans based on the patient's specific conditions and regularly monitor the progression of the disease so that treatment strategies can be adjusted in a timely manner.

In general,ribociclib (ribociclib) as a targeted therapy drug, has shown good efficacy and safety in the treatment of advanced breast cancer, providing an important treatment option for patients.